Chesnara PLC (LSE:CSN) has extended its streak of dividend growth to 20 years, thanks to rising cash generation and strong capital reserves. The company posted a 14% rise in commercial cash generation to £60 million in 2024, a solid profit jump, and says it’s actively looking for more deals.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) expects royalty income to rise sharply this year, boosted by higher copper and cobalt production across key sites. Cobalt deliveries from Voisey’s Bay could jump 90%, while expansion plans aim to ramp up revenue through to 2030.
HeLIX Exploration PLC (AIM:HEX) has kicked off civil works at its Linda-1 site in Montana ahead of drilling its third production well. Rig mobilisation is due soon, with helium processing equipment already being fabricated ahead of expected production.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) says its peanut allergy vaccine has hit a key trial milestone, with no safety issues in high-dose testing. Both healthy volunteers and allergic patients are progressing through dose escalation, with Phase IIb trials planned next.
Tissue Regenix Group PLC (AIM:TRX) has secured a European patent for its core dCELL technology, which underpins its regenerative medicine products. Already patented in the US and UK, the move strengthens global protection for its tissue scaffolds used in wound care and implants.
